(NASDAQ: RNA) Avidity Biosciences's forecast annual revenue growth rate of 125.43% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 97.96%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.83%.
Avidity Biosciences's revenue in 2025 is $20,868,000.On average, 15 Wall Street analysts forecast RNA's revenue for 2025 to be $2,582,732,894, with the lowest RNA revenue forecast at $797,376,027, and the highest RNA revenue forecast at $4,809,569,685. On average, 15 Wall Street analysts forecast RNA's revenue for 2026 to be $3,316,373,081, with the lowest RNA revenue forecast at $0, and the highest RNA revenue forecast at $10,346,903,203.
In 2027, RNA is forecast to generate $44,740,148,072 in revenue, with the lowest revenue forecast at $11,483,148,974 and the highest revenue forecast at $90,607,350,694.